News - Page 40 of 40

“Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.”

Ailawadhi, S., R. Sexton, S. Lentzsch, M. H. Abidi, P. M. Voorhees, A. D. Cohen, E. M. Rohren, S. Heitner, K. Kelly, N. J. Mackler, D. M. Baer, A. Hoering, B. Durie and R. Z. Orlowski
Clin Cancer Res, 2020.

“BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8(+) cytotoxic T lymphocytes against multiple myeloma: clinical applications.”

Bae, J., N. Parayath, W. Ma, M. Amiji, N. Munshi and K. C. Anderson
Leukemia, 2020.

“Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.”

Bustoros, M., R. Sklavenitis-Pistofidis, J. Park, R. Redd, B. Zhitomirsky, A. J. Dunford, K. Salem, Y. T. Tai, S. Anand, T. H. Mouhieddine, S. J. Chavda, C. Boehner, L. Elagina, C. J. Neuse, J. Cha, M. Rahmat, A. Taylor-Weiner, E. Van Allen, S. Kumar, E. Kastritis, I. Leshchiner, E. A. Morgan, J. Laubach, T. Casneuf, P. Richardson, N. C. Munshi, K. C. Anderson, L. Trippa, F. Aguet, C. Stewart, M. A. Dimopoulos, K. Yong, P. L. Bergsagel, S. Manier, G. Getz and I. M. Ghobrial
J Clin Oncol, 2020.

“The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.”

Cho, S. F., L. Lin, L. Xing, Y. Li, K. Wen, T. Yu, P. A. Hsieh, N. Munshi, J. Wahl, K. Matthes, M. Friedrich, T. Arvedson, K. C. Anderson and Y. T. Tai
Blood Adv, 2020.

“BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.”

Cho, S. F., L. Lin, L. Xing, Y. Li, T. Yu, K. C. Anderson and Y. T. Tai
Cancers (Basel), 2020.

“Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120.”

Dhodapkar, M. V., R. Sexton, A. Hoering, F. Van Rhee, B. Barlogie and R. Orlowski
Clin Cancer Res, 2020.

“Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.”

Du, T., Y. Song, A. Ray, D. Chauhan and K. C. Anderson
Leukemia, 2020.

“Multiple myeloma: the (r)evolution of current therapy and a glance into future.”

Gulla, A. and K. C. Anderson
Haematologica, 2020.

“Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.”

Hideshima, T., D. Ogiya, J. Liu, T. Harada, K. Kurata, J. Bae, W. Massefski and K. C. Anderson
Leukemia, 2020.

“New Drugs in Multiple Myeloma.”

Kunacheewa, C. and R. Z. Orlowski
Annu Rev Med, 2019.

“Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.”

Baljevic, M. and R. Z. Orlowski
Expert Opin Drug Metab Toxicol, 2019.

“A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.”

Manasanch, E. E., G. Han, R. Mathur, Y. Qing, Z. Zhang, H. Lee, D. M. Weber, B. Amini, Z. Berkova, K. Eterovic, S. Zhang, J. Zhang, X. Song, X. Mao, M. Morgan, L. Feng, V. Baladandayuthapani, A. Futreal, L. Wang, S. S. Neelapu and R. Z. Orlowski
Blood Adv, 2019.